Note: This company is no longer actively listed. Financial data shown is historical.
Showing 2 of 10 years of data. Sign up free for 3 years, or upgrade for full access.
View Plans2-year trend showing gross, operating, and net profit margins
Dishman Pharmaceuticals & Chemicals 's net profit margin of 9.1% in FY2018 reflects thin profitability, with operating margin at 13.8% and gross margin at 80.1%.
In FY 2018, Dishman Pharmaceuticals & Chemicals posted a gross margin of 80.1%, an operating margin of 13.8%, a net margin of 9.1%. Gross Margin = (Revenue - COGS) / Revenue; Operating Margin = EBIT / Revenue; Net Margin = Net Income / Revenue. Typical healthy ranges: Gross 20-40%, Operating 10-20%, Net 5-10%+. Consistent or improving margins indicate strong competitive positioning.
2-year trend showing revenue, gross profit, and net profit
Dishman Pharmaceuticals & Chemicals 's revenue declined 1.1% to 16.95B in FY2018, though net profit grew 6.3% to 1.55B.
In FY 2018, Dishman Pharmaceuticals & Chemicals 's revenue declined by 1.1% year-over-year. Revenue is total income from operations. Gross Profit is revenue minus cost of goods. Net Profit is the bottom line after all expenses. Consistent growth across all three signals a healthy, expanding business.
2-year trend showing shareholder returns
Dishman Pharmaceuticals & Chemicals 's ROE of 3.0% in FY2018 indicates weak shareholder returns.
In FY 2018, Dishman Pharmaceuticals & Chemicals reported an ROE of 3.0%. ROE = (Net Income / Shareholders' Equity) x 100. Measures how efficiently the company turns equity into profit. Above 15% is generally strong; above 25% is excellent. Very high ROE may signal high leverage — check alongside debt levels.
2-year trend comparing profitability with cash generation
Dishman Pharmaceuticals & Chemicals 's FCF/NI ratio of 0.06x in FY2018 indicates weak cash generation raising concerns about earnings quality.
In FY 2018, Dishman Pharmaceuticals & Chemicals 's free cash flow trailed net income. Free Cash Flow = Operating Cash Flow - Capital Expenditure. When FCF exceeds net income, it suggests high-quality, cash-backed earnings. Persistent gaps may indicate aggressive accounting or heavy capex needs.
2-year trend comparing profitability with cash from operations
Dishman Pharmaceuticals & Chemicals 's OCF/NI ratio of 1.47x in FY2018 indicates strong cash collection and working capital efficiency.
In FY 2018, Dishman Pharmaceuticals & Chemicals 's operating cash flow exceeded net income. Operating Cash Flow is the actual cash from core operations. OCF exceeding net income signals strong cash collection. OCF trailing net income may indicate aggressive revenue recognition or working capital issues.
Measure a company's financial leverage, liquidity, and ability to meet financial obligations.
2-year trend showing short-term liquidity position
Dishman Pharmaceuticals & Chemicals 's current ratio of 1.31x in FY2018 indicates healthy short-term liquidity.
In FY 2018, Dishman Pharmaceuticals & Chemicals reported a current ratio of 1.31. Current Ratio = Current Assets / Current Liabilities. Measures short-term liquidity. A ratio of 1.5-3.0 is generally healthy; below 1.0 signals liquidity risk; above 3.0 may indicate underutilized assets.
2-year trend showing ability to service debt
Dishman Pharmaceuticals & Chemicals 's interest coverage ratio of 4.8x in FY2018 indicates adequate ability to service debt.
In FY 2018, Dishman Pharmaceuticals & Chemicals reported an interest coverage ratio of 4.8x. Interest Coverage = EBIT / Interest Expense. Shows how many times operating profit covers interest payments. Above 5x is comfortable; below 1.5x signals potential difficulty servicing debt.
2-year trend showing financial leverage and capital structure
Dishman Pharmaceuticals & Chemicals 's debt-to-equity ratio of 0.18x in FY2018 reflects a conservative, low-leverage capital structure.
In FY 2018, Dishman Pharmaceuticals & Chemicals reported a debt-to-equity ratio of 0.18. Debt-to-Equity = Total Debt / Total Equity. Below 1.0 is conservative; 1.0-2.0 is moderate; above 2.0 indicates higher financial risk. Capital-intensive industries naturally carry higher ratios.
2-year trend showing total debt with year-over-year changes
Dishman Pharmaceuticals & Chemicals 's debt increased 8.7% YoY in FY2018 — debt levels are increasing.
In FY 2018, Dishman Pharmaceuticals & Chemicals 's total debt increased by 8.7% year-over-year. Total Debt includes short-term debt, long-term loans, debentures, and capital leases. YoY changes (shown as percentages) reveal whether the company is leveraging up or deleveraging.
Year-over-year change in diluted shares outstanding
Dishman Pharmaceuticals & Chemicals 's diluted shares remained virtually unchanged in FY2018.
Over 2 years (FY2017–FY2018), diluted shares remained essentially unchanged at 161.39M.
In FY 2018, Dishman Pharmaceuticals & Chemicals 's diluted shares remained flat by 0.0% year-over-year. Diluted Shares accounts for stock options, warrants, and convertibles. Positive YoY change means dilution (red); negative means buybacks (green). Consistent dilution above 5% annually is a red flag.
You're viewing 2 years of data. Upgrade to access 10 years of financial ratios, margins, and performance metrics.
Data from audited consolidated filings. For educational purposes only — not investment advice. Last update: FY 2018